Status:

RECRUITING

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Lead Sponsor:

XSpline S.p.A.

Conditions:

Cardiac Resynchronization Therapy

Chronic Heart Failure

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective of this prospective, multicenter controlled study is to assess the feasibility of a patient-tailored implantation by creating a cloud-based pre-procedural multimodality CRT-roadmap by in...

Eligibility Criteria

Inclusion

  • Eligible subjects shall meet all following criteria:
  • Appropriately signed and dated informed consent.
  • Age ≥18 years at time of consent.
  • CRT indication according to the 2021 ESC guidelines on cardiac pacing and CRT (class I and IIA indication in patients with LBBB QRS morphology) or to 2017 AHA/ACC/HFSA guidelines (COR I).
  • Sinus rhythm
  • QRS duration ≥130 ms
  • Left bundle branch block
  • Left ventricular ejection fraction ≤35%
  • Symptomatic heart failure NYHA class ≥ II
  • Documented stable medical treatment for at least 6 months
  • No cardiovascular intervention during the last 6 month
  • Exclusion Criteria are:
  • History of persistent or permanent atrial fibrillation
  • Previous pacemaker or ICD implantation
  • Indication to pacing due to bradycardia
  • Patients considered for His bundle pacing or cardiac conduction pacing
  • Patients with unstable angina
  • Subject experienced a recent myocardial infarction, within 40 days prior to enrollment
  • Subject underwent coronary artery bypass graft or valve surgery, within 90 days prior to enrollment
  • Subject is post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year
  • Subject is implanted with a left ventricular assist device
  • Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure
  • Subject has severe aortic stenosis (with a valve area of \<1.0 cm2 or significant valve disease expected to be operated within study period)
  • Subject has congenital heart disease
  • Subject has a mechanical right-sided heart valve
  • Subject has a life expectancy of less than one year in the opinion of the investigator
  • Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control
  • Subject is enrolled in one or more concurrent studies that would confound the results of this study
  • Patients who have contraindications to CT scanning.
  • Patients with chronic kidney diseases and estimated glomerular filtration rate (eGMR) calculated based on CKD-EPI 2009 \< 40 ml/min/1.73m2

Exclusion

    Key Trial Info

    Start Date :

    March 6 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 1 2025

    Estimated Enrollment :

    150 Patients enrolled

    Trial Details

    Trial ID

    NCT05327062

    Start Date

    March 6 2023

    End Date

    September 1 2025

    Last Update

    October 24 2024

    Active Locations (13)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (13 locations)

    1

    Rush University Medical center

    Chicago, Illinois, United States, 60637

    2

    The University of Chicago Medicine

    Chicago, Illinois, United States, 60637

    3

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114

    4

    Duke University Hospital

    Durham, North Carolina, United States, 27710